Live Breaking News & Updates on Genitourinary Cancers|Page 6

Stay updated with breaking news from Genitourinary cancers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Higher-Dose RT Extends Survival in High-Risk Prostate Cancer

Adding higher dose radiation led to long-term ADT led to better progression-free, cancer-specific, and overall survival vs standard-dose radiation in men with high-risk prostate cancer. ....

United States , France General , Neha Vapiwala , Christophe Hennequin , American Society For Clinical Oncology , Radiation Therapy , Treating Patients Receiving Hormone Therapy , Prostate Cancer , Clinical Oncology , Genitourinary Cancers , Hospital Saint Louis , Penn Medicine , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Of The Prostate , Alignant Neoplasia , Alignant Neoplasm , Etastatic Carcinoma , Metastatic Cancer , Biologic Therapy , Prostate Specific Antigen , Sa Prostate Specific Antigen , Lymph Nodes ,

Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer

OS, PFS, cancer-specific survival all improved, with no increase in toxicity ....

France General , United States , Charles Bankhead , Neha Vapiwala , Christophe Hennequin , Tumor Group , Saint Louis Hospital , Genitourinary Cancers , French Genito Urinary Tumor Group , Penn Medicine , Androgen Deprivation Therapy , Medpage Today ,

What's Going On With ESSA Pharma Stock Today? - ESSA Pharma (NASDAQ:EPIX)

ESSA Pharma shares fell 22.6% at $6.80 yesterday. Explore masofaniten's promising Phase 1/2 results in prostate cancer treatment. Updated data, PSA reductions, and financial strength. ....

Pharma Inc , Benzinga Pro , Genitourinary Cancers ,

Why Is Precision Oncology-Focused Corbus Pharmaceuticals Stock Trading Higher Today? - Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharma's CRB-701 exhibits 43% ORR and 71% disease control in urothelial cancer trial. ....

United States , American Society Of Clinical Oncology , Corbus Pharmaceuticals Holdings Inc , Clinical Oncology , Genitourinary Cancers ,

Cabometyx, Tecentriq stave off prostate cancer progression as Exelixis joins Novartis on FDA's wait list

Cabometyx, Tecentriq stave off prostate cancer progression as Exelixis joins Novartis on FDA's wait list
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United States , Roche Tecentriq , Amy Peterson , Exelixi Cabometyx , Neeraj Agarwal , University Of Utah , American Society Of Clinical Oncology , Clinical Oncology , Genitourinary Cancers , Fierce Pharma ,